Emerging evidence strongly suggests that treating male sexual partners can cut the recurrence of bacterial vaginosis roughly in half. A landmark randomized trial published in the New England Journal of Medicine in 2025 found that when male partners received a week-long course of antibiotics alongside the standard treatment their female partner was already getting, recurrence within 12 weeks dropped from 63% to 35%. The trial was actually stopped early because withholding partner treatment from the control group was deemed unethical once the data became clear. This finding reshapes decades of clinical thinking that dismissed men as bystanders in BV.
Why BV Recurrence Has Been So Stubbornly High
Standard antibiotic treatment for BV works well in the short term, with 30-day cure rates approaching 80% for a typical course of oral metronidazole.1PubMed Central. Understanding and Preventing Recurring Bacterial Vaginosis: Important Considerations for Clinicians The problem is what happens afterward. An unacceptably high proportion of women experience BV recurrence within six months, and for many women, the cycle repeats for years.2PubMed Central. Bacterial vaginosis: drivers of recurrence and challenges and opportunities in partner treatment The bacteria involved in BV form a stubborn polymicrobial biofilm on the vaginal lining, which can be difficult for antibiotics to fully eradicate.3PubMed Central. Fighting polymicrobial biofilms in bacterial vaginosis But even when treatment does clear the biofilm, something keeps reintroducing those bacteria. For a long time, researchers debated whether that something was the male sexual partner.
BV Bacteria Live on Men Too
Men don’t get bacterial vaginosis in any clinical sense. They don’t develop symptoms the way women do, and there is no “male BV” diagnosis. But the bacteria that cause BV in women can and do colonize the penis, particularly under the foreskin and in the urethra. A study of over 250 men found that key BV-associated species, including Leptotrichia/Sneathia and Atopobium, were detectable in roughly 8 to 12 percent of participants.4PubMed Central. Bacterial Vaginosis–Associated Bacteria in Men: Association of Leptotrichia/Sneathia spp. With Nongonococcal Urethritis These organisms were often found together rather than alone, mirroring the community-style growth pattern seen in vaginal BV.
The more telling finding comes from couples research. When scientists compared the bacterial communities on penile skin and in the urethra of men whose female partners had BV, those communities looked significantly more similar to their partner’s vaginal microbiota than to any random woman with BV.5PubMed Central. Bacterial communities in penile skin, male urethra, and vaginas of heterosexual couples with and without bacterial vaginosis In couples where the woman had a healthy vaginal microbiome, this kind of partner-specific bacterial overlap did not show up. In other words, BV bacteria are shared between specific partners, not just floating around in the general population.
Gardnerella vaginalis, the species most associated with BV, provides some of the strongest evidence for this partner sharing. A study that used fine-grained genetic analysis of Gardnerella strains in monogamous couples found that in over half of couples where both partners carried the bacterium, the specific subtypes were highly correlated between the woman’s vaginal samples and the man’s penile or urethral samples.6PLoS ONE. Exploring the Diversity of Gardnerella vaginalis in the Genitourinary Tract Microbiota of Monogamous Couples Through Subtle Nucleotide Variation Gardnerella biofilm, the sticky community structure that makes BV so hard to eradicate, has been identified on penile tissue as well, and appears to be sexually transmitted between partners.7Gynecologic and Obstetric Investigation. Gardnerella Biofilm Involves Females and Males and Is Transmitted Sexually
Is BV Actually a Sexually Transmitted Infection?
This has been one of the most contentious questions in sexual health for decades. BV doesn’t behave like a classic sexually transmitted infection in some important ways: it occurs in women who have never had sex, it doesn’t always follow the contact-tracing patterns of gonorrhea or chlamydia, and it has no single causative organism. Some researchers have preferred to call it a “sexually enhanced disease,” meaning that sexual activity increases risk without being strictly necessary for it to develop.8PubMed Central. The epidemiology of bacterial vaginosis in relation to sexual behaviour
But the epidemiological data tell a story that looks increasingly STI-like. A systematic review and meta-analysis found that having new or multiple male partners raised the relative risk of BV by about 60%, having any female sexual partner doubled it, and consistent condom use was associated with a modest reduction in risk.9Clinical Infectious Diseases. Sexual Risk Factors and Bacterial Vaginosis: A Systematic Review and Meta-Analysis The review concluded that the overall epidemiological profile of BV is similar to that of established STIs. A 2025 narrative review reinforced this, noting that in the few studies evaluating both penile and vaginal microbiomes simultaneously, specific bacterial taxa are highly correlated, with evidence for transmission in both directions.10PubMed Central. Role of the penile microbiome in female sex partner risk of bacterial vaginosis and sexually transmitted infections: a narrative review
The debate matters because the label shapes treatment policy. If BV is sexually transmitted, treating only one partner while the other continues to harbor the same organisms is like mopping the floor while leaving the faucet running.
The StepUp Trial Changed the Conversation
For years, clinical guidelines did not recommend treating male partners of women with BV, and for seemingly good reason: earlier randomized trials had tried it and found no benefit. A well-known 1997 trial gave male partners either oral clindamycin or placebo and found virtually identical recurrence rates in the women, about 31% in both groups.11Sexually Transmitted Infections. Treatment of male partners and recurrence of bacterial vaginosis: a randomised trial That trial, along with several others from the same era, became the basis for the longstanding position that partner treatment doesn’t help.
The key insight that changed things came from microbiology rather than gynecology: BV-associated organisms don’t just live in the urethra. They also colonize the penile skin, particularly the subpreputial space under the foreskin. Older trials used oral antibiotics alone, which are effective against bacteria in the urethra but do a poor job reaching organisms living on external skin. Researchers in Australia designed the StepUp trial around a combination strategy: male partners received both oral metronidazole tablets and topical clindamycin cream applied to the penile skin, both twice daily for seven days.
The results were striking. In the group where only the woman was treated (standard care), 63% experienced BV recurrence within 12 weeks. In the group where the male partner also received the combined treatment, recurrence dropped to 35%.12New England Journal of Medicine. Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis The independent safety monitoring board halted the trial early because continuing to withhold partner treatment from the control arm was no longer ethical given how large the benefit was.13PubMed Central. Advances in treating bacterial vaginosis: recognizing sexual transmission and pipeline of therapies By targeting bacteria in both the urethra and on penile skin, the trial provided what many researchers consider definitive evidence that the male genital tract acts as a reservoir driving BV recurrence in female partners.
Why the Older Trials Failed
Knowing why earlier studies found no benefit helps explain why clinical thinking was stuck for so long. The 1997 trial and others like it treated men with oral antibiotics only. Oral clindamycin or metronidazole can reach bacteria in the urethra through the bloodstream, but the bacteria living on penile skin, especially under the foreskin, sit outside the reach of systemic antibiotics. It’s a bit like treating a skin infection with a pill when you really need a cream. The bacteria on the surface survive, the man reintroduces them during sex, and the woman’s BV returns.
The StepUp trial’s dual approach, hitting both the urethral and skin reservoirs simultaneously, addressed this gap. The combination of oral metronidazole for internal colonization and topical clindamycin for the penile surface was specifically designed to match where the bacteria actually live. This design detail is probably why a treatment that had “failed” in earlier studies suddenly produced a large and statistically robust effect.
What Treatment Looks Like for Men
In the StepUp trial, the male regimen was straightforward: metronidazole 400-mg tablets taken twice daily plus 2% clindamycin cream applied to the penile skin twice daily, both for seven days.12New England Journal of Medicine. Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis The man begins treatment at the same time as his female partner starts her own BV antibiotics. The topical component is applied to the entire penile shaft and under the foreskin (for uncircumcised men), where the highest concentrations of BV bacteria tend to reside.
The side-effect profile in the trial was manageable. Metronidazole can cause nausea and a metallic taste, and it interacts badly with alcohol, so men need to avoid drinking during the course. Clindamycin cream can cause mild skin irritation. Qualitative research found that men who went through the treatment largely considered it acceptable and were willing to do it for their partner’s benefit.14PubMed Central. “It’s just an issue and you deal with it… you just deal with it, you move on and you do it together.”: Men’s experiences of bacterial vaginosis and the acceptability of male partner treatment The framing mattered: when men understood that the treatment was about solving a recurring problem as a couple rather than implying blame or infidelity, they were generally on board.
Does BV Affect Male Health Directly?
Mostly not. In the absence of symptoms in themselves, BV had little measurable health impact on men beyond their concerns for their partner’s well-being.14PubMed Central. “It’s just an issue and you deal with it… you just deal with it, you move on and you do it together.”: Men’s experiences of bacterial vaginosis and the acceptability of male partner treatment Some researchers have looked at whether BV-associated bacteria cause non-gonococcal urethritis (NGU) in men, but a study of over 300 men found no significant association between the presence of key BV organisms and NGU diagnosis.15PubMed Central. Bacterial vaginosis-associated bacteria in cisgender men who have sex with women: prevalence, association with non-gonococcal urethritis and natural history So the rationale for treating men isn’t really about the man’s own health. It’s about breaking the cycle of reinfection in his partner.
There is one exception worth knowing about: fertility. In couples trying to conceive, the presence of BV-associated bacteria in semen has been linked to abnormal semen parameters, including altered viscosity and higher rates of abnormally shaped sperm.16PubMed Central. Male Partners of Infertile Couples With Seminal Positivity for Markers of Bacterial Vaginosis Have Impaired Fertility Laboratory research has gone further, showing that toxins produced by BV bacteria can disrupt the process by which sperm become capable of fertilizing an egg. When mouse and human sperm were exposed to BV-associated toxins, their motility decreased and their ability to undergo the final maturation steps needed for fertilization was impaired.17PubMed Central. Bacterial Vaginosis Toxins Impair Sperm Capacitation and Fertilization This is still early-stage research, but it raises the possibility that for couples struggling with infertility, addressing BV in both partners might matter for reasons beyond just preventing recurrence.
BV Transmission Between Women
Male partner treatment is relevant to heterosexual couples, but BV transmission between female sexual partners is well established and arguably even more clear-cut. A study of monogamous lesbian couples found that when an index partner had BV, her partner was nearly 20 times more likely to also have BV compared to partners of women without BV.18PubMed. Bacterial vaginosis in lesbians: a sexually transmitted disease A systematic review confirmed this pattern, finding that increased numbers of female sexual partners and having a partner with BV were both strongly associated with BV diagnosis, supporting the concept of sexual transmission between women.19PLOS ONE. Factors Associated with Bacterial Vaginosis among Women Who Have Sex with Women: A Systematic Review
The StepUp trial focused on male partners, so no equivalent randomized trial has yet tested concurrent treatment of female sexual partners. But the biological logic is arguably even more straightforward: if both partners have a vaginal environment, and BV-associated bacteria are readily shared during sexual contact, treating only one woman while the other retains the same bacterial community creates the same reservoir problem that drives recurrence in heterosexual couples. Clinicians who work with women who have sex with women increasingly recommend that both partners be evaluated and treated when one has recurrent BV, though formal clinical trial data to guide this are still needed.
Circumcision and the Penile Microbiome
The foreskin appears to play a meaningful role in BV transmission. The warm, moist subpreputial space under the foreskin provides a favorable environment for anaerobic bacteria, including the species most closely associated with BV. Research from Uganda found that male circumcision reduces the load of BV-associated bacteria on the penis and decreases BV rates in female partners.20PubMed Central. Penile Microbiota and Female Partner Bacterial Vaginosis in Rakai, Uganda This aligns with the broader observation that circumcision alters the penile microbiome in ways that reduce several sexually transmitted infections.
This doesn’t mean circumcision is a treatment for BV or that uncircumcised men are “responsible” for their partner’s condition. Circumcised men still carry BV-associated bacteria, just at lower levels on average. And the StepUp trial included men regardless of circumcision status and found benefit from antibiotic treatment across the board. But the circumcision data reinforce the same underlying point: the penile surface is a bacterial reservoir, and anything that reduces the bacterial load there appears to help.
The Emotional and Relationship Dimension
Recurrent BV carries a psychological burden that is easy to underestimate. Qualitative research with couples has identified three overlapping areas of impact: the physical symptoms themselves, the psychological toll of repeated episodes and failed treatments, and the strain on relationships when one partner is dealing with a chronic, stigmatized condition. Women described frustration, cost, and inconvenience from being treated alone over and over while the problem kept returning.21PubMed Central. Getting Everyone on Board to Break the Cycle of Bacterial Vaginosis (BV) Recurrence: A Qualitative Study of Partner Treatment for BV
When concurrent partner treatment was introduced, both men and women described it as a turning point. The shift from an individual problem to a shared one changed the dynamic. Men who understood the rationale were willing to participate and reported feeling that they were doing something constructive rather than being sidelined. Women felt less isolated. Healthcare providers who explained the treatment in terms of shared biology rather than blame or infidelity found that couples engaged more readily with the approach. The framing matters as much as the prescription pad: BV is not something one partner “gave” the other, but something the couple’s shared microbiome perpetuates, and treating both partners addresses the biology rather than assigning fault.
Where Guidelines Stand Now
The StepUp trial results were published in early 2025, and clinical guidelines in most countries have not yet formally incorporated concurrent male partner treatment into standard recommendations. Guideline updates tend to lag behind individual trials, even landmark ones, because committees typically wait for replication studies, cost-effectiveness analyses, and safety data from broader populations. In Australia, where the trial was conducted, some sexual health clinics have already begun offering the combined oral-plus-topical regimen to male partners off-label, and experts have called for rapid guideline revision.
In the United States, the situation is more complicated. The specific metronidazole tablet dose used in the StepUp trial (400 mg) is not the formulation typically available in the U.S., where 500-mg tablets are standard. Clindamycin 2% cream is available but is not currently indicated for penile use. Prescribing these medications for a male partner would be off-label, meaning insurance coverage could vary and some pharmacists might question the prescription. None of these are insurmountable barriers, but they do mean that implementation will require clinical awareness and some advocacy on the part of both providers and patients. If you or your partner deals with recurrent BV, bringing the StepUp trial results to your doctor’s appointment is a reasonable step while formal guidelines catch up.
Practical Considerations for Men Offered Treatment
If your female partner has recurrent BV and a clinician recommends concurrent antibiotic treatment for you, a few things are worth knowing. You will not have symptoms of BV yourself, and there is nothing wrong with your health in the conventional sense. The treatment isn’t about you being sick; it’s about clearing a bacterial reservoir so that the same organisms don’t get passed back to your partner after she finishes her own course. Both of you should complete the full seven days, avoid sex during treatment (or use condoms), and avoid alcohol while taking metronidazole.
The topical clindamycin cream should be applied to the full penile shaft, including under the foreskin for uncircumcised men, since the subpreputial space harbors the densest populations of BV-associated bacteria. The cream can weaken latex condoms, so if you’re relying on barrier protection during the treatment period, non-latex options are a better choice. Most men in the StepUp trial tolerated the regimen without major issues, and the overall side-effect profile was consistent with what you’d expect from common antibiotics rather than anything unusual or harsh.